BackCERo Therapeutics Holdings - Warrants (13/02/2029) Overview
CERo Therapeutics Holdings Inc. - Warrants (13/02/2029)

CERo Therapeutics Holdings - Warrants (13/02/2029) Return on Equity

Latest ROE for CERo Therapeutics Holdings - Warrants (13/02/2029): 416.3% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

416.30%

Return on Equity

416.30%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) FAQ

CERo Therapeutics Holdings - Warrants (13/02/2029)'s return on equity stands at 416.3%. That is above the sector sector average of 11.64%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CERo Therapeutics Holdings - Warrants (13/02/2029) sits higher the its sector benchmark (11.64%) with a ROE of 416.3%. That is roughly 3477.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 416.3% for CERo Therapeutics Holdings - Warrants (13/02/2029) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how CERo Therapeutics Holdings - Warrants (13/02/2029)'s ROE evolved across reporting periods, while the comparison chart places CEROW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.